Chemotherapeutic effects of different paclitaxel plus poldine combination methods for treatment of ovarian carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 7, 2011, Pages 1713-1716

  Liu, Ying Lan ^a   Zhang, Ya Ling ^a   Fu, Jian Hua ^a   Zhang, Guang Mei ^a  

^a HARBIN UNIVERSITY   (China)

Author keywords

Combined chemotherapy; Ovarian carcinoma; Taxoere paclitexal

Indexed keywords

ANTINEOPLASTIC AGENT; BENZILIC ACID DERIVATIVE; DOCETAXEL; PACLITAXEL; POLDINE METHYLSULFATE; TAXOID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZILATES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 84861454239     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Abaid LN, Lopez KL, Micha JP, et al (2010). Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity. Eur J Gynaecol Oncol, 31, 308-11.
2. Akeson M, Zetterqvist BM, Dahllof K, Brannstrom M, Horvath G (2008). Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up. Acta Obstet Gynecol Scand, 87, 1343-52.
3. Chen XS, Nie XQ, Chen CM, et al (2010). Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol, 21, 961-7.
4. Hornychova H, Melichar B, Tomsova M, et al (2008). Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest, 26, 1024-31.
5. Jin C, Wu H, Liu J, Bai L, Guo G (2007). The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells. J Clin Pharm Ther, 32, 41-7.
6. Kovacs P, Csaba G (2006). Effect of drugs affecting microtubular assembly on microtubules, phospholipid synthesis and physiological indices (signalling, growth, motility and phagocytosis) in Tetrahymena pyriformis. Cell Biochem Funct, 24, 419-29.
7. Kumar S, Mahdi H, Bryant C, et al (2010). Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health, 2, 411-27.
8. Lentini A, Tabolacci C, Mattioli P, Provenzano B, Beninati S (2010). Antitumor activity of theophylline in combination with Paclitaxel: a preclinical study on melanoma experimental lung metastasis. Cancer Biother Radiopharm, 25, 497-503.
9. Samuel T, Fadlalla K, Turner T, Yehualaeshet TE (2010). The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycle. Nutr Cancer, 62, 1025-35.
10. van de Steeg E, van Esch A, Wagenaar E, et al (2011). High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res, 17, 294-301.
11. Wang C, Gu M, Wang S, Ma D (2000). Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer. J Tongji Med Univ, 20, 343-44.
12. Yacoub A, Liu R, Park MA, et al (2010). Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependen melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol, 77, 298-310.